Inovio Pharmaceuticals (INO) 10 Aug 212021 Q2 Earnings call transcript

Good afternoon, and welcome to the Inovio Second Quarter 2021 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Ben Matone, Senior Director of Investor Relations. ahead. go Please

Good Inovio operator. thank for you Thank quarter afternoon, XXXX the second earnings joining you, and conference call.

today's Peter Kate Vice and Jackie Vice President Joining and Broderick, Scientific Officer; Dr. Senior on call Clinical Mammen, Joseph Chief Dr. Development. me Senior Anza Kim, Laurent CEO; Humeau, Mr. Research Chief Development; Kies, President Shea, Dr. of of Dr. CFO; Operating Officer; are President and Dr.

the corporate today's ended second we for review financial For quarter our XX, and call, XXXX. June information will

prime-boost company's We both China, will well DNA partner updates, Medicines we'll DNA developments programs address of well Phase this our global vaccine morning's and discuss therapeutic COVID-XX vaccine our our recent current concern, press for trials heterologous candidate, platform. efforts as as development Among clinical our our release as associated Advaccine. address various to variants with INNOVATE the X our trial Inovio's and recent pertaining future relating with COVID-XX INO-XXXX, in to as

prepared segment analysts. reserved conducting for a remarks, question-and-answer research be equity we Following will

DNA results SEC beliefs with time documents capital or to forward-looking Inovio's data During the timing readouts, relate regarding the will assist discovery plans we materially to activities expressed resources materially. you expectations the concluded. uncertainties differ which, applicable of website, related and are the partners, our and file as and under these management available in today. with we that to in on All time to our be important strategic statements the clinical products events actual which Medicine, events regulatory could ir.inovio.com, and matters. associated with We could being business identify based market. the from of Actual performance including, on clinical regulatory results the requirements, a making to potentially statements without These developments business the by third refer of future future is to events be platform, the call, Factors, integrated and include of company. to from and develop and differ and verbally has cause clinical This conducting our compliance cost to risks our will today; writing party Risk level trials, on of call call dependence made development and limitation, this factors those replay company collaborative with and heading bringing live after shortly along webcast

the Joseph call I CEO, Now, Inovio's Dr. over President turn Kim. would to and like to

time join you, call. afternoon, need number to Thank rapidly Good additional vaccines, variant. and Ben. you for particularly could Delta recognizes today's capabilities again and offer globally first-line us With the including infections, COVID-XX for combat and rates of the taking those the surging increasing for thank Inovio breakthrough spreading potential spread safe effective emerging boosting and variants, the of which virus the then to

advantages as want booster a have reviewing and of we prevent only broadly realize be In strategy a pandemic, to needs committed offer we that as platform. most by advance to Medicines globally to COVID-XX to to vaccine potentially a Inovio's spend INO-XXXX leveraging used first-line Inovio's INO-XXXX both our call key and DNA vaccine As of today, this response global the potential an across organization, are but health public I the short to medicines address in the more areas. present therapeutic time to DNA not

of Specifically, concern. believe alongside T-cells generate the we ability the Medicines which in neutralizing mitigating against robust platform rising to advantages include variants of be antibodies, crucial DNA key will our

to that. preprints, of our our through morning's being can This and These globally; immunogenicity trial inactivated CoronaVac, Advaccine regulators, sponsor or for validated received trials healthy the vaccine regulatory widely and COVID-XX begin in INO-XXXX. recent will which which Both evaluate Organization have and safety, wonderful countries XX concerns heterologous adult done publications by are prime-boost announcement and Sinovac tolerability Sinovac, also tolerability, immunizations shown key working accessible anticipated with vaccines initiatives. be made older. and will example transportability some clinical acknowledged DNA be differentiators, boosting for subjects World with Health supply to vaccine use. These profiles. an and the Our for further of a developed validated of through together sequential favorable thermostability involve partner INO-XXXX China which ensuring investigating been and fall trials, essential are heterologous medicines using conducted allowance are in years have that will and this two trials emergency of Inovio is Advaccine a be a of age China by

antibodies potential booster does of and not INO-XXXX use prime-boost to of vaccines really well-positioned challenge variants will the vaccines. not the ever. around ACE tests antigen-specific be important this cases an increased for the by of an enable to Sinovac T-cell concept especially tolerability, against in and the key of action, as as and contagious as Sinovac to serving evaluated to partnership We're the believe its heterologous abilities likely With assay, Advaccine vaccine to protect a a using COVID-XX expand a efficient immune-boosting immune and is our potentially to responses, high provide strategies to work solution immunogenicity explore safer preclinical the with that than require CoronaVac. expanding balanced become strong COVID-XX heterologous profile needs booster of its the Delta and INO-XXXX with prime-boost strategy the thermostability to against to and believe binding prime-boost cold market responses. and the level completed in serve other primary our recently We will live-virus prime-boosting enhances forward vector or receptor-blocking antibodies, Inovio and that factor variants to data world, is look other mRNA these with a a vaccine by viral variant excited both excited along Advaccine animal the perhaps of increasing of these concern that of can due global important fighting ultra-cold-chain more and synergistically sharing of both vaccine trials, cross this of INO-XXXX. We we development INO-XXXX well future. vaccines. as global current only transport. COVID-XX trials Advaccine proud more If and neutralization Helping potentially assay the community may that highly be inactivated concerns, but Results the different neutralizing component from immune with demonstrated immune-enhancing vaccine, real-world antigen-specific to stimulate with continued and We're due see mechanisms for cross-reactive vaccine people the approved, as and more and

next Latin our initiated older further, the in like we expanding Asia, specifically, reiterate trial trial month US. on More Inovio's countries and focus concentrating INNOVATE focus go America, I healthy is Before X to in across XX trials countries, addition our Africa. this getting men enroll outside to starting and would executing to on Phase and several women non-pregnant primary years the to global

for the on the enrolling United As plan States, US subjects not does the in any it trial. Inovio INNOVATE relates Phase X to

responses INO-XXXX showed T-cell the Pan-COVID neutralizing compared fully study in particular, INO-XXXX, T-cell maintained and the is In parallel original also this Subsequent T-cell to Inovio discuss by efficacy to a of formal preprint that of strain, the for used COVID other and immune trial. showed and novel first-generation platforms. in with quarter, variant and boosting INO-XXXX adenovirus primary Broderick responses the update once the to landscape. hold vaccination global level company preprint INO-XXXX, INNOVATE BLA be a provided while -- vaccination to as when Dr. similar the the humans Kate variants is capabilities addition well Returning global I'd to strain. X With like level against Delta vaccine, to clinical and in the published changing specifically cross-reactive In an Phase Anza protect both Mammen, on who similar a progress. variants wildtype to to showing was that homologous activity will by against our We Gamma the of INO-XXXX Anza? it INO-XXXX, that also with In pandemic vaccines. released approval lifting regimen as and wildtype compared something will the antibody turn are X partial on Both the the a now call and/or is Phase against INO-XXXX maintain INO-XXXX a responses to the to reduced when US is as FDA work, variant an of demonstrated INO-XXXX the for later, trial responses vaccine responses Delta the of INO-XXXX the a leading INO-XXXX second Alpha, a our to to including future that, a long-term current found heterologous designed able which generated other to the offer vaccination the broad developing part as engage initial in T-cell vaccines, second-generation pursue potentially VOC. results plans boosting. as both original mRNA-based a Beta, against candidate, broad concern. were could against Dr.

Thank you to on I'm with Joseph. glad call today. here the be you,

efficacy to in announced partnership the be INO-XXXX. for primarily significant. trial Latin mentioned Advaccine This sites our will conducted Joseph our continues virus where X remarks, As and opening transmission jointly be we in at Asia his countries, Phase several conduct across expansion multiple America global to of trial with

the emergency in limited unmet the a been currently globally. recently have to trial authorized being INNOVATE vaccines use need as We with X countries remains expand available Africa in administered access Phase to discussions there and significant

assay INO-XXXX X evaluate Phase antibody X age healthy the administered recent rise well-tolerated in regimen a we two geometric XX clinical across and and study and maintenance fold ELISpot Phase also the in immunogenic Phase measured the Notably, two-milligram-dose builds date, activity, particular, of randomization these The responses SARS-CoV-X back the that, With concern. greater a as I picture a variants years using of individuals, of the the the humoral be we've against INNOVATE for demonstrating tested and the we well the the to reminder, two-milligram-dose the call two-to-one in group cross-reactive combat of one the compared the a group and a group. to where quarter, X presented women versus responses all two-dose now done all variants dose together potential month in INO-XXXX and of data findings to one-milligram-dose will were apart will in cellular neutralizing as and everything comprehensive higher Taking older. INO-XXXX the mean In in of trial to T-cell conveying milligrams statistically one-milligram-dose levels emerging were provide group. immune efficacy especially binding INO-XXXX of found upon T-cell Joseph. work second significant vaccinated that non-pregnant by groups. to As the future men immune and results as over turn of safety that

Anza. Thanks,

remarks, focused Senior diseases. As our INO-XXXX efficacy well extremely opening infectious detail to on trials, Broderick, our in in INO-XXXX, Inovio's as Phase I candidate, parallel we're Dr. speak about in as with I'll the also work Pan-COVID X R&D, efforts our vaccine mentioned greater broader advancing DNA while ask during VP Kate? second-generation of Kate my through INO-XXXX. now developing

are earlier Joseph, in us candidate, today. parallel to to who's everybody developing the the on call with Pan-COVID we outlined INO-XXXX Thank the hello In a call, second-generation vaccine INO-XXXX. you, efforts also and

vaccine companies is capabilities In could INO-XXXX our including first-generation INO-XXXX an with important concern. mRNA-based XXXX, potentially viral demonstrated or Inovio's INO-XXXX both inactivated, variant published manuscript platforms. wildtype-matched strategy Immunogenicity have Pan-COVID-XX and website initial current previously against additional either current INO-XXXX variants individuals our developed next-generation various candidate, a other asset boosting and/or vaccination of in vaccines, with which shift, -- future and as as the vaccine entitled, as viral in preprint for a Design portfolio. immune and matched-strains, adenovirus, on potentially Synthetic anticipate immunized addition booster of an to using DNA variants makes a offer other While bioRxiv a Vaccine, vaccines. emerging May a Pan-SARS-CoV-X cross-reactive We regime and Inovio INO-XXXX, which first-line against responses

the for also as and near wildtype details forward progress Gamma, Beta, Alpha, look sharing Specifically, subsequent against We animals against well in XXXX we've research, INO-XXXX T-cell Delta our with induced more a responses neutralizing the X/X variant. on future. clinical to all-important Phase trial to with can the prepare against and as that original we fully And found variants. also strain, potent INO-XXXX in protect vaccinated the antibody

volunteers. Our Phase DNA for work last tolerability Inovio's by sponsored quarter, for Coalition which earlier, funded Respiratory our CELLECTRA the but as This XX% or and the and of diseases global reported. INO-XXXX, placebo-controlled, Inovio is Inovio our outlined East is INO-XXXX device those builds COVID-XX in approximately or evaluates vaccine cases INO-XXXX, infectious being are as is deep immunogenicity sites This Epidemic administered MERS. coronavirus roots the commitment the clinical study, our in X our have to where infected. fatality program, both smart Syndrome, who late-stage also Jordan trial currently and on multicenter advancements in which preclinical Lebanon, for well CEPI, in on for adult Anza with rate Innovations, health. dosed is XXX MERS, is using candidate just vaccine approximately trial double-blinded, safety, by our a first Preparedness been There MERS conducted X public Phase The subject Middle healthy INO-XXXX, and no our of as randomized, at approved

vaccines Our as a vaccine vaccine pursuit Phase previously Inovio's clinical X MERS completion I Fever. Lassa make available candidates you, to successful against as is turn CEPI, of CEPI's well And and Phase will testing. $XX million will from a funded emergency back grant now, It through announced Joseph. following MERS use under by develop Inovio goal remains to of which MERS stockpile X a call the of for

Kate. Thank you,

you I'd with on update a programs. CFO, our other for provide an like quarter, financial Before to provides clinical Kies, our important summary the Peter

administration. responses follow following squamous HPV-related lesions, for months of XX, HSIL, high-grade for VGX-XXXX or our advancing of we cervical our XX in safety trials REVEAL HPV HPV pivotal treatment subjects durability two disease and/or First, to treatment X, by the and caused continue research, one intraepithelial of X Phase last evaluating the for XX

the present at XXXX, full subject-level facilitate of anticipate detailed We from which individual will scientific unblinding data. REVEAL second findings our expect meeting patient-level later X in to and year, a this of analysis half

findings adult confirmed biomarker to QIAGEN these we clinical with X, this X/X year. In clinical to decision-making year. total cervical Sanofi across medicines women addition, globally, being a inhibitor of an is quarter INO-XXXX with anticipate and survival our sharing efforts, fourth DNA Phase XX XXX our use look immuno-oncology this novel jointly developed and in combination X to oncology from INO-XXXX co-developing in treating reporting the combination We Phase Inovio with with partners and Regeneron HSIL. guide sites second findings data REVEAL in pivotal Among of continue the Inovio PD-X overall evaluate continues enrollment approximately enroll VGX-XXXX later and cervical the newly diagnosed projected to the two-year HSIL, for checkpoint histologically GBM. in of is trial, Libtayo, of conference at our by forward which

Next, financial over quarter Peter? will for I second the turn our to call summary. Peter

second of the cash, capital equivalents investments, providing cash programs. sufficient with us years and activities short-term support We with everyone. $XXX.X afternoon, and Good existing ended multiple Joseph. quarter in to Thanks, million

of Our same compares in which revenue for XXXX second the was the period to XXXX. quarter $XXX,XXX $XXX,XXX, for

net total loss million share, basic quarter and operating expenses dilutive, million period which of million, the to $XX.X per was to per Our XXXX in the quarter $X.XX for or for Inovio's ended or June $XX.X compares of second net basic $XX.X $X.XX XX, compared loss a were million for share, XXXX. XXXX. and the $XXX.X dilutive, same

attributable CELLECTRA engineering increase development These recorded grant million activities -- contra-research offset scale-up period compares increases from drug included automation expenses in and INO-XXXX. services the $XX.X expense our outside compensation increase to trial. expenses drug for to of variances. device was employee project, expenses equipment manufacturing equipment R&D in included were primarily services These related of activities RRP agreements XXXX. for an and to and in expenses installation the increases to among and for million, expense. R&D to related manufacturing the manufacturing, which equipment, other of clinical Our array contractor INO-XXXX million acquisition quarter and XXXX, same our related second by $X.X were $XX.X The XPSP study Other also and manufacturing

which versus second in increases expenses in for an XXXX related XXXX. Lastly, I'll were over back the includes turn by of G&A primarily G&A non-cash the Joseph. employee performed partially stock-based quarter in compensation. compensation, offset $XX.X increase This for that, related you, $XX.X among to period was marketing And with expenses lower to work was million corporate expenses variances. These communications, other for to it same million and

Peter. you, Thank

entire as as extend differentiators DNA dedication to analyst of to appreciation diseases. hard patients questions, and to with the and of Inovio work what INO-XXXX. T-cell of take as collaborators, as and of response unmet medicines for we I Inovio. in are ability and my your would needs one funders well and support ability like team protect meaningful with development continued strong In support, evolving and We all well are acknowledge a approaches partners, to diseases, profile, as addressing across confident in their we thank COVID-XX benefits our Before and other to cancer offer our you as vaccines HPV-associated broadly, development. a COVID-XX and DNA health programs and best our and modern against the efforts, dedicated thermostability for the believe tolerability The our closing, functional to fighting and medicines antibody global infectious remain well generate like

call the open for now will We Operator? questions. your

Instructions] from session. question go first with comes ahead. Please America. of the begin [Operator now The will Geoff Bank Meacham We question-and-answer

taking for question. you Geoff on our This afternoon. [ph] Thank Good is Alex for Meacham.

So, I'll have two from us.

can your and moving to variants affected strategies enrollment then the X in trial? platform, release immuno-oncology is, you. path the the glioblastoma? expand any And you one what for how has your COVID-XX to with the first in is FDA? discussions the cases And the you can regulatory your speak overall timelines Thank data and for increase forward, Phase overall rise on The of

I'll we're address to Yes. Alex. then impact the on X. the is Glioblastoma tracking on Thank trial, Phase Anza enrollment your I'm for landscape changing and patients. Dr. Mammen you, to question question, second address briefly, the going ask which first still the

and data developing We sharing reported a regulators. OSXX the data in be the forward on and on this will that presentation updates at that time from conference at our will look thoughts those further the program as fourth quarter, have we a to additional

So Anza, enrollment like strategy of ask part the the to address I'd you landscape. our to XXXX changing first in

Joseph. Thank Yes. you,

So to [ph] vaccination to and in X, virus begin to rates virus rapidly And with America initially, still with you light administer two the bring changing two-region regards countries, study landscape light development and the of especially the well, as an in Phase for -- Asia-Pacific. begin also we've to on low recently within the now biomarkers as design relatively INO-XXXX And COVID-XX. of rates and to doses region. INNOVATE involving to in these transmission know we've of regards embarked strategy continent on a the subjects continued the adopted vaccination changing of with confirmed follow and overall is to the epidemiology African approach that Latin

of our as real-time be taking an these able are to the countries, to across really preparing the enrollment as data we epidemiology. in countries vaccination able with real-time rates to focus in approach comes the approach cases enroll of virus to regards that be and to regions take understanding shift in are three virus multiple to as these reported the being well in So,

in, enroll where way, kind as COVID-XX this to our to in be bring we of the maintain optionality So necessary optimally, cases. to to able

question. your answers this hopefully, So

sure. color. Thank the you for so For much

Singh with Please The Oppenheimer. ahead. next Hartaj is from go question

One that and X of the progress previous a couple is world. on just you're be conducting your question questions. going Thanks following Great. to the for parts of up with various update, in the Phase

variants did ran seem many, but I up medicines-based, to time not have you a also indicated where there. the likely regards? Phase one. in the not that included of very excisions. be thanks in really run of had Again, us previous having to your against are lady surgical thoughts necessarily those companies, call have for mean, surgery could you the They How on try have your variants are uptake uncomfortable strategy that's Number efficacy. that physician the reported KOL to year, where a kind and the trials They're Can What with been from Some would have a your address be specifically a strain were against younger a so in and last Wuhan to more DNA avoid that, HSIL X, questions. trials them. increase a about vaccine that they strategy with two VGX-XXXX? there. a then efficacy certain lesser few Joe, biomarker to cropped these think we all And time. women other HSIL,

Thanks, Yes. Hartaj.

let address So, me very quickly.

Kate but touched our and Wuhan speak, we various -- happen to including responses studies, second INO-XXXX these sort originally good in done, in of neutralization I strain, studies T-cell as challenge variants. so on found also pretty think incredibly, vaccine -- against against XXXX well INO-XXXX that, Anza and protection to as designed strain various the has we've what right? was wildtype both overall going is it's So, X the half, Phase but in approach, the

we're allows a the lucky execute efficiently that have from information mentioned, would different three center Africa. a we continents; America, by these making sort like So, those X to most partners as enrollment help encouraged dedicated that. Asia, supportive we're command us to us decisions of Anza employees, very Latin based team information we're And And and of collaborators on trial, of coming Phase that real-time data. INNOVATE such and and run have

on we're interim of efficacy. we're forward trial, the and looking INNOVATE with the XXXX of year the first for next to getting potential readout very and half in So, the bullish data

absolutely question that to. So of your your HSIL. I agree you which with second referring cervical important then -- part is and also were KOL the is

who with have or the current potential their to looking surgery the one right now form even the carry women of older in future has at impact cervix, another, think HSIL it on pregnancies. women, tremendous treatment it's to a and I younger negative or of ability

If you're be. a LEEP in see a you how curious, the procedure such and surgery traumatic could Google YouTube, just

-- and next X this year we're is REVEAL X should it data VGX-XXXX dataset be INO what we what the presents, and So, year, the REVEAL have that -- full could in first the treatment not non-surgical and eradicate viruses virus, immunotherapy-based also for HPV the only disease women clear or treat disease, that in the first place. but to cause XX the XX

surgery So, we're scraping very potential much any What can without future excited about the the their a to what health present of layers this pregnancies. new with and the in their they and don't to a product VGX-XXXX cancer. market generation optionality or a cervix potential who to top either now treat choice; is potentially of of patients, will VGX-XXXX off right women's have developing bring impairing it's

So, thank you very much for that question.

you, Great. Thank Joe.

ahead. next with Gregory The go question RBC Capital. is Please Renza from

the on target to from enrollment to update as REVEAL if you once learnings event and just taking if Hey, that, on my Joseph, the Joseph, HSIL. potential it's the I'm just -- Joseph comes I'd along side and then, discussion could when just data point in updates that questions. indicated, or I to design additional on X XXXX REVEAL you're a collected. of in Thank your there momentum think disclosed the help for the early you any is in a maybe adjustments trial the or Thanks. readout that if there. perhaps perhaps incorporating it curious, for parallel cervical X way. the just device BLA for just provide and thereafter get team. filing sort finer are some And an and curious just I'm

Yes. Thanks, Greg.

now. enrolling is X REVEAL So,

We fully to the enroll before end of year. the expect

on any based made look. haven't We X adjustments interim the REVEAL

X this and dataset also We of have REVEAL before of will a REVEAL a eventful end data X to have year, well. the year as the very the have we're will second of from going the readout we biomarker also as full half

this will way our of the a lot So, go full a positioning for dataset long information REVEAL in VGX-XXXX. program for

REVEAL trials, CELLECTRA of the move being commercial that X will are forward and X system we we all BLA be at the XPSP delivery data Phase confident we REVEAL as clinical hand. is for currently used terms So in have the for our devices, ready to of and conduct intramuscular device application commercialization once the X very

CELLECTRA So, XPSP device. in we're our very confident

Peter. Great, from multiple years And maybe mentioned for thank the last runway you programs Peter, across a just me, you. one for cash multiple [indiscernible].

Yes.

context this the I'm around these you again, over the just the we curious your portfolio. other in about COVID would In Thank across the trajectory of programs if then come, some and quarter, well to vax that just spreads for maybe quarters the programs, certainly maybe spend color some anticipate provide that you could thoughts how as as allocation very much guys.

equipment well that's was device around installation and manufacturing as launch, as for scale-up. of Yes. A the INO-XXXX the lot -- the increase acquisition of most the

starting expect what now in last running year, one used of we actually existing in of just million spike. forward for for of the kind be completed was bit quarter production. see is summer going [ph]. as that early up high and to -- A to it's going lot brought was going the what burn expect now expenses a it's little number this facility somewhere $XX our been forward had and purchased expense looked in it's like forward we'll But quarters and we a a So, the and to of us

Per month?

Per month, yes.

Great. Peter. Thanks,

sorry. Okay, questions? more Any

Thanks, guys.

H.C. with go ahead. Please Chen Yi from is question Wainwright. Next

Chen. of behalf [indiscernible] two is I questions. on this Hey, have Yi

the you boosting Sinovac and of start enrollment? plan first second The of Advaccine will is, MERS do What vaccine know X one to China a be The complete question And the could you trials enrolled? target one, the you. study is, the Phase in when when when enrollment? little ago, number study it to while many but spoke last report about is top-line results? expect and X previously just Thank REVEAL the subjects do heterologous how I

is responses trial as and data the it of remarks, then XXX In second expect prepared fall study, the in to and of this before X immune was around the half of first enrollment, the readout have the start Yes. 'XX; REVEAL XXXX; in this mentioned order; XXXX. trials end part to safety the data expect MERS year, data prime-boost we early X first half of and in we reverse people, Phase in

you Thank much. so

thanks. Yes,

The with Group. Maxim next from ahead. Please McCarthy go question is Jason

line specific in that with contact the the some everyone. It's could on Thanks just the was Africa, respect Hey, America platform. regions [ph] who if and regulators Dave Latin Asia, my you question. for in and taking shed on been with I to Jason. wondering for INO-XXXX you've color --

Yes.

So, countries approved different to certainly Phase are or those America, stating those some the governments Asia, in Latin the Africa specifically region. from that X is not regions, other proposal our -- some impacts. and floated in influence But evaluating governments not they're presentation of of just to publicly until seen you've we're they various course these in

also in when are quality trials, each different the approach ways the these similar in So, many each regulators countries of make but in you country. there standards how executing are sure highest you're have to

and a collaborators. efforts, on execute with been efforts dedicated our consultants along significant has by our these this So, to Inovio team

to next come the that September. So, been work expect results of very INNOVATE in pleased And the see first of we've and Phase initiation these you soon we should we're the fruition. be the month X hard some with making our trial, results, efforts and to launching

excited about progress. So, our we're very

path And agreement that additional with it partnership the assuming entry platform, color. that saying just COVAX you I'm fact chain of Sinovac, storage, require the the -- I'm the guys have you've the that? doesn't on said Great. in some I then Am Thanks cold or potential have you everything into right program. yes, INO-XXXX and assuming based of for a sort about

unlayer a question Well, your just me so let make and correction.

safety Our of doing prime-boost and of the WHO what in is said certainly you Inovio, of China, with candidates of profile most global also trial, partnership all factor requirement attribute like cold our important Advaccine the what key morning. Advaccine certainly absolutely COVAX, one we're favorable correct. platforms being safety INO-XXXX you're there. vaccine think pipeline important of lack out profile-generating freezers many XXXX INO-XXXX profile one program reported a the Sinovac what's very or two entities But these transport. and not full I with for different with we of generating. studies the is And others, supply deep to and been that's requiring in meaning have along this that about and and of That's a was tolerability chain It's store

of case in with other our vaccine real tolerability T-cells we stability safety, So, either the temperature of favorable regimens, many responses the generate boosting on profile advantage think puts to above platforms. having ability antibody and of the us top schemes or really primary along

So, we're first. very excited about that. Obviously, first things

data and of aspects, a next through half announced year. But other Phase that We and trial. prime-boost have execute the the getting month XXXX. the lot to other and Sinovac have of test boostability looking with today. We're We going next forward that these of including Advaccine would INNOVATE we efforts to we efficacy with X our regimens in first starting our the do demonstrate to that

So, exciting in data information to a coming lot the months. come and of

I additional appreciate for thanks it. Okay, the color.

you. thank Yes,

Jefferies. is with next go Chikere from question ahead. Kelechi Please The

you Yes, I thank clinic? comprehensive you. [indiscernible]. update but the Have -- here. Thank hi. it, I XXXX the provided have importantly for guess enter timeline on updated will when And have you missed provided you an may more

variant, potential profile interesting very unknown is I this for -- an really for durability a for think vaccine. Coverage

finer I guess a on just put this to point [ph]?

And Kelechi. Kate. go Thank I just -- you, ahead, No, would

enter could when it going if about I you was clinic, to you mind. ask the don't just potentially

we're go sorry, ahead, Kate. Yes, --

it We're more be able firm as we'll update working incoming to very hard as clinic that provide on possible, and the soon into to calls. get

XXXX, development more fully now, strategies up forward. enrolling give and the positive trials Right the X of Phase we're that. up top going extremely it INNOVATE we this. this but of a think I efficacy in standing on demonstrating all-in about little And XXXX for of in just have platform for setting color also impact this starting would and important data XXXX, full efficacy trial to we is nearness also And Yes. and the would talked

and focus information future But global That our X being calls. trial, out to the a So, Phase clinic, more bring excited I in in focus, INNOVATE our think XXXX is said, XXXX primary our behind the to very XXXX that. little but right we'll primary XXXX bring the trial. is we're is

thank you. Okay,

Yes, thanks.

Benchmark. Aydin from question Please ahead. go next Huseynov with The is

taking for you Thank questions. the

Hi, Aydin.

Joseph. Hi,

company, efficacy vaccine a their about India-based have XX% There's reported I So, an DNA of question patients. vaccine. DNA Zydus, they on XX,XXX

So, Thank ballpark how do DNA expected that the for compares vaccine is reported of you efficacy think INO-XXXX number kind do think they you you. to efficacy? of this vaccine the and Zydus, the

for thanks the Yes, question.

did during I strong all, thing demonstrate XX%, was to think able a it's that great of in the variant of about efficacy they and height this spreading of the a Zydus Delta First India.

step give them the for DNA and vaccines important field we a that for full as So, a big this whole. kudos is

differences some Now, jet three Zydus' using Zydus are vaccinations. so electroporation as Inovio's you system. INO-XXXX a was Inovio injector, three-dose then in regimen, whereas between uses two-dose a is regimen. Inovio, And vivo a and vaccine. Zydus is know, the there CELLECTRA different

We electroporation have efficient of over CELLECTRA these systems plasmids. -- other DNA we in delivery and vivo others like have delivery published mechanisms more on for

very of another over to get very INO-XXXX data, to that trial we're sort other because see for -- and we Zydus' a advantages better. planning DNA, to think we we'll to think it of can the we're So, has data -- hope driver have but even as and if we're certainly the Obviously, just lot getting going serves do Zydus' us Phase but demonstrate as well. -- trial, for our the platforms X executed and and not urgent encouraged by we hoping in and that we're excited

achieving Zydus we but of we for give efficacy, kudos -- hopeful that as lots go we can for forward. and that we're that top So

you. Okay, thank

Thanks, Yes. Aydin.

session. any This the closing back I would to to over like Joseph the for turn Kim concludes conference question-and-answer remarks.

Yes. updates call. We Q&A. very Thank Thank you sharing quarter look to much. prepared and next to the to look great forward much our a third we very in forward for you those both and listening remarks the

presentation. you today's concluded. for has attending Thank now conference The

You may now disconnect.